National Jewish Health

About: National Jewish Health is a healthcare organization based out in Denver, Colorado, United States. It is known for research contribution in the topics: Asthma & T cell. The organization has 883 authors who have published 833 publications receiving 79201 citations. The organization is also known as: National Jewish Medical and Research Center.

Measuring Neutrophil Bactericidal Activity.

Abstract: The best-known role of neutrophils is control of pathogen growth. Neutrophils contain and kill pathogens through a variety of antimicrobial activities. Regardless of the mechanism, the ability to kill pathogens is a vital outcome. This chapter describes a method to measure the in vitro bactericidal activity of isolated neutrophils as the endpoint of converging innate immune functions.

Covalent binding of leukotriene A4 to nucleosides, nucleotides, and nucleic acids.

Abstract: The chemical reactivity of leukotriene A4 (LTA4) is widely appreciated following the detailed studies of its stability in aqueous solutions, solutions containing organic solvents, and solutions containing albumin [1]. The half-life of LTA4 is less than one second unless a stabilizing substance is present in aqueous buffers. This has led to the concept that intracellular LTA4 exists only for a brief period of time before it is either nonenzymatically hydrolyzed to 6-trans-LTB4 isomers or converted by LTA4 hydrolase or LTC4 synthase into the biologically active leukotrienes, LTB4 and LTC4, respectively [[2]]. The reactivity of LTA4 is due to its electrophilic character and within the cell various nucleophiles are present including nucleic acids which could, in theory, donate electrons into the conjugated triene epoxide moiety of LTA4.

Drug Resistance Assays for Mycobacterium tuberculosis

Abstract: The introduction of antimicrobial therapy of tuberculosis during the second half of the last century was a turning point in the millennium-old history of this disease. However, the problem of drug resistance emerged, and with it, two levels of concern. First, such resistance not only poses a public health threat to successful control of TB epidemics, but it also complicates the approach to treatment of individual patients. In previous reviews we have addressed the history of research and evolution of views based on these studies

Non-response to Communication Technology Outreach for Beta-agonist Overuse in a Pragmatic Randomized Trial of Patients with Asthma.

Abstract: Evidence suggests that communication technology applications can improve treatment adherence.1 However, a recent Cochrane Review concluded insufficient evidence exists to determine the effects of automated communication on managing chronic conditions such as asthma.2 Because not all patients are receptive to communication technology interventions, defining factors associated with non-response to electronic outreach can inform tailoring future interventions to increase effectiveness. As part of a pragmatic trial targeting asthma patients with too frequent refills of inhaled beta-agonists (“overfill”),3 the objective of this work was to describe and compare patients who did versus did not respond to a communication technology outreach. A higher asthma medication ratio (AMR), defined as the ratio of asthma controller medications (numerator, e.g., inhaled corticosteroids) to total controller medications plus inhaled beta-agonists (denominator), is associated with better asthma outcomes.4 We hypothesized that patients who did not respond to outreach would have a lower AMR than patients who did respond.